GSK, mRNA and influenza vaccine
Shares of GSK PLC GSK dropped 1.38% to £16.10 Tuesday, on what proved to be an all-around favorable trading session for the ...
GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...
British drugmaker GSK said on Wednesday its experimental herpes simplex virus (HSV) vaccine candidate failed to meet the main ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...
GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage ...
GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.
GSK PLC GSK shares inched down 0.09% to £16.32 Monday, on what proved to be an all-around favorable trading session for the ...
12h
Drug maker GSK plc (GSK, GSK.L) announced Tuesday that Blenrep (belantamab mafodotin) combinations in relapsed/refractory multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback